Multiple Sclerosis
Multiple Sclerosis (MS) is an autoimmune neurological disease that damages the myelin sheaths insulating nerve cells in the brain and spinal cord, disrupting signal transmission and causing symptoms such as muscle weakness, vision problems, and impaired coordination, which can appear in isolated attacks or progressively worsen over time.
Health Outcomes
- Activated Mitophagy Pathway
- Additional Therapeutic Benefits
- Adjusted Immune Function
- Altered CD4+ T-cell Cytokine Levels
- Altered CD4+/CD8+ Ratio
- Altered Chemokine Response
- Altered Endocannabinoid System Function Due to Specific Strain
- Altered Expression of Immune Products
- Altered Expression of Immune-Related Genes
- Altered IFN-γ Levels
- Altered Lymphocyte Subset
- Altered Serum IL-6 Levels
- Altered Serum Immune Protein Levels
- Altered Systemic Immune Response
- Altered T Cell Migratory Behavior
- Altered T Cell Subsets
- Balanced T-Cell Differentiation
- Beneficial Clinical Effects
- Changed Brain Activity
- Changed Functional Connectivity
- Changed Thermal Detection Threshold
- Changed Walking Cadence
- Changed Wind-Up Ratio
- Chronic Immune Activation
- Decreased Composite Scores
- Decreased Immune Response to Influenza Vaccination
- Decreased Naïve CD45RA+ T Helper Cells
- Decreased Peripheral CD3⁺ T Lymphocyte Count
- Decreased Peripheral T Cell Response
- Decreased TNF-α Production in Immune Cells
- Decreased Vastus Medialis Thickness
- Delayed Disease Progression
- Duration of Symptoms
- Elevated IgG1 Levels
- Elevated Interferon-β Levels
- Elevated Interleukin-10 Levels
- Elevated Interleukin-12 Levels
- Elevated Interleukin-17 Levels
- Elevated Serum IFN-γ Levels
- Elevated Serum IL-2 Levels
- Elevated TNF-α Expression Level
- Enhanced Adjuvanticity
- Enhanced Anti-Inflammatory Cytokine Secretion
- Enhanced Antioxidant Capabilities
- Enhanced Autophagy
- Enhanced Cell-Mediated Immunity
- Enhanced Cognitive Function
- Enhanced Cytokine Production
- Enhanced Functional Traits
- Enhanced IL-12 Production
- Enhanced Immune Cell Activity
- Enhanced Immune Function
- Enhanced Immune Function Post-Cessation
- Enhanced Immune Memory
- Enhanced Immune Modulation
- Enhanced Immune Regulation
- Enhanced Immune Response
- Enhanced Immune Signaling Molecule Production
- Enhanced Immune System Function
- Enhanced Immunogenicity
- Enhanced Immunomodulation
- Enhanced Immunomodulatory Function
- Enhanced Immunoregulatory Function
- Enhanced Immunoregulatory Molecule Activity
- Enhanced Interferon Gamma Production
- Enhanced Interleukin-10 Production
- Enhanced Lymphocyte Proliferation
- Enhanced Neurogenesis in Adults
- Enhanced Neurological Disorder Management
- Enhanced Phenotypic Maturation of Dendritic Cells
- Enhanced Radical Scavenging Ability
- Enhanced Regulatory Immune System Development
- Enhanced Regulatory T Cell Development
- Enhanced Regulatory T Cell Function
- Enhanced Serum ACH50 Activity
- Enhanced Strength
- Enhanced T- and B-Lymphocyte Proliferation
- Enhanced T-Cell Proliferation
- Enhanced T-Cell Response
- Enhanced Tolerance Acquisition
- Enhanced Treg Cell Differentiation
- Enhanced Type 1 Immune Response
- Identification of FDA Approved Drug Target Regulators
- Improved 6-Meter Walk Performance
- Improved 6-Minute Walk Test Distance
- Improved 6-minute Walking Distance
- Improved Activities of Daily Living
- Improved Activities of Daily Living Score
- Improved Agility
- Improved Agility Performance
- Improved Agility and Coordination Performance
- Improved Antigen-Presenting Ability of Dendritic Cells
- Improved Antioxidant Defense
- Improved Ataxia
- Improved Ataxia Rating Scale Score
- Improved Average Power During Leg Press
- Improved Balance
- Improved Barthel Index
- Improved Barthel Index Score
- Improved Bench Press 1-RM Strength
- Improved Berg Balance Scale
- Improved Blood-Brain Barrier Function
- Improved Blood-Brain Barrier Integrity
- Improved Brain Activity
- Improved Brain Health
- Improved Cell Survival Rates
- Improved Cell-mediated Immunity
- Improved Cellular Immune Response
- Improved Cellular Immunity
- Improved Central Nervous System Function
- Improved Cerebellar Ataxia
- Improved Chair Rise Performance
- Improved Clinical Activity
- Improved Clinical Disease Activity
- Improved Clinical Efficacy
- Improved Clinical Outcomes
- Improved Clinical Remission
- Improved Clinical Success
- Improved Cognition
- Improved Cognitive Orientation Function
- Improved Cognitive Performance
- Improved Cognitive Status
- Improved Communication
- Improved Communication Skills
- Improved Constipation Management
- Improved Constructional Praxis
- Improved Cytokine Levels
- Improved Cytokine Production
- Improved Cytoprotection During Oxidative Stress
- Improved Daily Activity Participation
- Improved Decision Accuracy
- Improved Dendritic Cell Activation
- Improved Digit Symbol Substitution Test Score
- Improved Disability Score
- Improved Disease Control
- Improved Disease Management
- Improved Distance Traveled
- Improved Diversification of B-Cell Populations
- Improved Ejaculatory Function
- Improved Endurance
- Improved Endurance Power
- Improved Exercise Duration
- Improved Fatigue
- Improved Fatigue Index
- Improved Fatigue Ratio
- Improved Fatigue Resistance
- Improved Fatigue Symptoms
- Improved Fatigue Threshold
- Improved Fatigue Tolerance
- Improved Fatigue-Associated Features
- Improved Fine Motor Skills
- Improved Five Times Sit-to-Stand Time
- Improved Force Production
- Improved Function
- Improved Function Score
- Improved Functional Ability
- Improved Functional Activity
- Improved Functional Ambulation Classification
- Improved Functional Capacity
- Improved Functional Exercise Capacity
- Improved Functional Outcome
- Improved Functional Prognosis
- Improved Functional Recovery
- Improved Functional Status
- Improved Gait Speed
- Improved General Activity
- Improved Global Quality of Life
- Improved Glutathione Level
- Improved Glutathione Redox Ratio
- Improved Gross Motor Function
- Improved Hand Function
- Improved Health-related Quality of Life
- Improved Humoral Immunity
- Improved IL-10/TNF-α Ratio
- Improved IgG Response to Vaccination
- Improved Imaging Findings
- Improved Immune Activation
- Improved Immune Cell Counts
- Improved Immune Cell Function
- Improved Immune Parameters
- Improved Immune Regulation
- Improved Immune Response in Individuals with Poor Pretreatment
- Improved Immune System Function via JAK-STAT Pathway Activation
- Improved Immune System Maturation
- Improved Immune System Modulation
- Improved Immune Tolerance
- Improved Immune-Related Symptoms
- Improved Immunity Pathways
- Improved Immunoinflammatory Markers
- Improved Immunostimulatory Activity
- Improved Interleukin-10 Levels
- Improved Intestinal Transit
- Improved Isokinetic Strength
- Improved Jump Height
- Improved Knee Extensor Peak Torque
- Improved Knee Extensor Strength
- Improved Leg Extension Strength
- Improved Leg Press Performance
- Improved Leg Strength
- Improved Lower Body Endurance
- Improved Lower Body Muscular Endurance
- Improved Lower Body Power
- Improved Lower Limb Maximal Neuromuscular Performance
- Improved Lower Limb Peak Power
- Improved Lower Urinary Tract Symptoms-Related Quality of Life
- Improved Lower-Body Muscular Strength
- Improved MMSE Score
- Improved Maximal Power
- Improved Maximal Voluntary Isometric Contraction Force
- Improved Maximal Walking Performance
- Improved Maximum Urinary Flow Rate
- Improved Mean Power Output
- Improved Mini-Mental State Examination Score
- Improved Mobility
- Improved Mobility Score
- Improved Motor Function
- Improved Motor Outcome
- Improved Motor Score
- Improved Motor Skill Development
- Improved Motor Speed
- Improved Motor Symptom
- Improved Multiple Sclerosis Course
- Improved Multiple Sclerosis Symptoms
- Improved Muscle Function Recovery
- Improved Muscle Integrity
- Improved Muscle Spasm
- Improved Muscular Endurance
- Improved Natural Killer Cell Function
- Improved Neck Maximal Voluntary Isometric Contraction
- Improved Neurodegenerative Disease Symptoms
- Improved Neurodegenerative Disorder
- Improved Neurological Health
- Improved Neurological Parameter
- Improved Neurological Symptoms
- Improved Neuromuscular Function
- Improved Neuromuscular Power
- Improved Neuromuscular Strength
- Improved Neuroplasticity Biomarkers
- Improved Neuroprotection
- Improved Number of Throw per Set
- Improved Overall Cognitive Function
- Improved Overall Patient Outcomes
- Improved Overall Symptom Relief
- Improved Oxidative Stress Resistance
- Improved Oxidative Stress Tolerance
- Improved PHA-Induced Cytokine Production
- Improved Pacing
- Improved Paired Associate Learning
- Improved Passing Performance
- Improved Patient Global Impression of Change (PGI-C) Scores
- Improved Perceived Exertion
- Improved Peripheral Blood Lymphocyte Proliferation
- Improved Photopic Negative Response Amplitude
- Improved Physical Domain Score
- Improved Physical Function
- Improved Physical Mobility
- Improved Physical Performance
- Improved Physical Quality of Life
- Improved Physical Role Limitation
- Improved Physical and Cognitive Performance
- Improved Physical and Psychological Performance
- Improved Power-Related Outcome
- Improved Processing Speed
- Improved Psychomotor Skill
- Improved Psychomotor Speed
- Improved Quadriceps Function
- Improved Quadriceps Strength
- Improved Quality of Life
- Improved Quality of Life Score
- Improved Radial Deviation
- Improved Rate of Force Development
- Improved Reaching Ability
- Improved Regulatory T Cell Function
- Improved Relapse-Free Survival
- Improved Remission
- Improved Repetitions to Failure
- Improved Responder Rate
- Improved Role Physical
- Improved Role Physical Health
- Improved Secondary Symptoms
- Improved Self-assessed Disability
- Improved Sensorimotor Function
- Improved Simulated Game Total Completion Time
- Improved Sit-to-Stand Test Performance
- Improved Six Minute Walking Distance
- Improved Spasticity
- Improved Speech Function
- Improved Speech Reception Threshold
- Improved Spleen T-Cell Function
- Improved Sprint Power Output
- Improved Sprint Repeat Task Performance
- Improved Sprint Time
- Improved Squat Jump Performance
- Improved Standing Balance
- Improved Static Balance
- Improved Strength
- Improved Strength-Endurance Mean Velocity
- Improved Stroop Word Test
- Improved Superoxide Dismutase Activity
- Improved Swallowing Function
- Improved Symptom Control
- Improved Symptom Relief
- Improved Symptoms of Chronic Condition
- Improved Systemic Immune Response
- Improved Systemic Immunity
- Improved T Helper Cell Count
- Improved T Lymphocyte Subset Balance
- Improved T-Cell Cytokine Production
- Improved T-cell Proliferative Response
- Improved Th1 Immunity
- Improved Th1/Th2 Balance
- Improved Th17/Treg Ratio
- Improved Therapeutic Efficacy
- Improved Therapeutic Potential
- Improved Time to Exhaustion
- Improved Timed Up and Go
- Improved Timed Up and Go Performance
- Improved Timed Up and Go Test
- Improved Timed Up-and-Go Test Performance
- Improved Tiredness Symptom Score
- Improved Tolerance
- Improved Trail Making Test Time
- Improved Transit Time
- Improved Treatment Response Rate
- Improved Treg/Th-17 Balance
- Improved Upper Body Muscular Endurance
- Improved Upper Limb Maximal Neuromuscular Performance
- Improved Urinary Frequency
- Improved Vaccine Efficacy
- Improved Verbal Episodic Memory
- Improved Verbal Fluency
- Improved Vigor
- Improved Visual-Motoric Coordination
- Improved Visual-Spatial Function
- Improved Visuo-Cognitive Processing
- Improved Walking Ability
- Improved Walking Distance
- Improved Walking Speed
- Improved Wechsler Memory Scale Score
- Improved Wingate Peak Power
- Improved Working Memory
- Improved Working Memory Speed
- Increased 24,25(OH)2D Level
- Increased 3-Hydroxykynurenine to Kynurenine Ratio
- Increased Activation of Regulatory T Cells
- Increased Anti-Inflammatory Immune Cell Populations
- Increased Anti-Inflammatory Levels
- Increased Anti-inflammatory Cytokines
- Increased Anti-inflammatory Phenotype in Dendritic Cells
- Increased Anti-inflammatory to Pro-inflammatory Cytokine Ratio
- Increased Antibody Production
- Increased Antioxidant Activity
- Increased Antioxidant Potential
- Increased Apoptosis
- Increased Apoptosis in T Cells
- Increased B Cell Count
- Increased B Cell Populations
- Increased Brain Choline Level
- Increased CD3 Level
- Increased CD3+CD4+IFN-γ+ T Cell Count
- Increased CD4+CD25+ T Cell Numbers
- Increased CD4-Positive T-Lymphocytes
- Increased CD8 Level
- Increased CD8 Percentage
- Increased CD8+ T-Cell Count
- Increased CSF2 Level
- Increased Circulating 25-Hydroxyvitamin D Levels
- Increased Constipation Risk
- Increased Cytokine Production
- Increased Cytokine Production in Peripheral Blood Mononuclear Cells
- Increased Cytokine Response
- Increased Expression of Activation Markers on NK Cells
- Increased Fall Risk
- Increased Fatigue Threshold During Exercise
- Increased Foxp3 Protein Levels
- Increased Foxp3+ to IL-10 Ratio
- Increased Functional Capacity
- Increased GSH/GSSG Ratio
- Increased Glutathione Disulfide Ratio
- Increased Glutathione Peroxidase Levels
- Increased Helper T Cell Activation
- Increased IFN-gamma Secretion from Naïve T Cells
- Increased IFN-γ Level
- Increased IFN-γ Levels
- Increased IFN-γ to IL-4 Ratio
- Increased IL-12 Levels
- Increased IL-12 Production
- Increased IL-12 Production in Splenocytes
- Increased IL-17A Level
- Increased IL-2 Secretion
- Increased IL-6 Levels in Early Phase
- Increased Immune Activation without Cytotoxicity
- Increased Immune Cell Activity
- Increased Immune Cell Presence
- Increased Immune Factor Levels
- Increased Immune Marker Activation
- Increased Immune Marker Levels
- Increased Immunosuppressive Cytokine Production
- Increased Interferon Beta Levels
- Increased Interferon Gamma to Interleukin 10 Ratio
- Increased Interferon-Alpha Production
- Increased Interferon-Gamma Levels
- Increased Interleukin 12 Secretion from Dendritic Cells
- Increased Interleukin-10 Levels
- Increased Interleukin-10 Production
- Increased Interleukin-12 Production
- Increased Interleukin-12p40 Production
- Increased Interleukin-2 Production
- Increased Interleukin-2 to Interleukin-10 Ratio
- Increased Length
- Increased Lesion Detection Rate
- Increased Lymphocyte Proliferation
- Increased Maresin-1 Level
- Increased Memory T Cell Frequency
- Increased MicroRNA-146a Expression
- Increased Monocarboxylic Acid Transporter mRNAs
- Increased Myo-Inositol Level
- Increased NK Cell Level
- Increased Natural Killer Cell Count
- Increased Natural Killer Cell Frequency
- Increased Natural Killer T Cells
- Increased Need for Repeated Dosing
- Increased Nerve Growth Factor Level
- Increased Nerve Growth Factor Receptor Level
- Increased Nitric Oxide Secretion
- Increased Number of Persistent Diseased Sites
- Increased Osteopontin Level
- Increased Perceived Exertion
- Increased Peripheral Blood B Cell Frequency
- Increased Plasma Anti-inflammatory Cytokine Levels
- Increased Plasma Immunoglobulin Levels
- Increased Pro-inflammatory Cytokine IL-6
- Increased Pro-inflammatory Cytokine Production
- Increased Production of Anti-inflammatory Cytokine IL-10
- Increased Proportion of Activated T Lymphocytes
- Increased Proportion of CD45R+ B-cells
- Increased Proportion of Responders
- Increased Proportion of T Lymphocytes
- Increased Rating of Perceived Exertion
- Increased Regulatory T Cell Count
- Increased Regulatory T Cell Expansion
- Increased Regulatory T Cell Induction
- Increased Regulatory T Cell Populations
- Increased Regulatory T Cell Response
- Increased Regulatory T-Cells
- Increased Relative Weight of Immune Organs
- Increased Serine Level
- Increased Serum Immunoglobulins
- Increased Serum Interferon-Beta Level
- Increased Specific Antibody Production
- Increased Specific IgG Levels
- Increased Superoxide Dismutase Levels
- Increased T Cell Activation
- Increased T Cell Activation Marker Level
- Increased T-cell Proliferation at 12 Months
- Increased T-helper Type 1 Cytokine Concentrations
- Increased TNF-alpha Levels in Macrophages
- Increased TNF-α Production
- Increased Tetrahydrobiopterin Level
- Increased Th1-Associated Cytokine Release
- Increased Th17 Polarization
- Increased Time in Bed
- Increased Tolerability
- Increased Tolerogenic Dendritic Cells
- Increased Total Serum Antioxidant Capacity
- Increased Treg Cell Fraction
- Increased Type I Interferon Production
- Increased Walking Speed
- Induced Th1 Cytokines
- Influenced Systemic Immune Response
- Long-Lasting Immunomodulatory Effects After Weaning
- Maintained Cognitive Function
- Maintained Immune Homeostasis
- Maintained Physical Condition
- Modified Resting-State Brain Connectivity
- Modulated Cytokine Production
- Modulated Dendritic Cell Function
- Modulated Endocannabinoid System
- Modulated Host Response
- Modulated Humoral Inflammation
- Modulated Immune Cell Activity
- Modulated Immune Markers
- Modulated Immune Response
- Modulated Immune Tolerance
- Modulated Immunologic Response
- Modulated Inflammatory Cytokine Levels
- Modulated Innate Immune Response
- Modulated Lymphocyte Populations
- Modulated Multiple Sclerosis-Related Dysbiosis
- Modulated Peripheral Immune Response
- Modulated Systemic Immune Response
- Modulated Systemic Th1/Th2 Balance
- Nervous System Dysfunction in Host
- Neuroprotection in Neurodegenerative Diseases
- No Apoptosis in Peripheral Blood Mononuclear Cells
- No Clear Effect on Depression
- No Difference in Adverse Events
- No Increase in Fecal Incontinence
- No Significant Impact on Bacterial Community Composition or Diversity
- No Significant Improvement in Locomotor Activity
- Persistent Fatigue
- Post-Vaccinal Immunostimulatory Effect
- Preserved Wheel-Running Activity
- Prevention of Neurological Disorders
- Protection Against Oxidative Stress
- Rebalanced Th1/Th2/Th17 Cell Ratios
- Reduced 10-meter Walk Test Time
- Reduced 24-Hydroxycholesterol to Total Cholesterol Ratio
- Reduced 50-Meter Sprint Time
- Reduced 7-Hydroxycholesterol Level
- Reduced Accommodation Variability
- Reduced Anteroposterior Sway
- Reduced B Lymphocyte Proliferation
- Reduced Brain Atrophy
- Reduced Brain Inflammation
- Reduced Brain Oxidative Stress
- Reduced CD25+ Cells
- Reduced CD28 Expression Loss in CD8+ T Cells
- Reduced Cadence
- Reduced Central Nervous System Symptom Severity
- Reduced Chemokine Production
- Reduced Choking Index
- Reduced Clinical Relapse Rates
- Reduced Cognitive Fatigue
- Reduced Cognitive Function
- Reduced Cognitive Function Test Score
- Reduced Cognitive Impairment
- Reduced Composite Symptom Score
- Reduced Constipation
- Reduced Constipation Symptoms
- Reduced Cytokine Secretion in Dendritic Cells
- Reduced Days with Defecation Urgency
- Reduced Dendritic Cell Function
- Reduced Digit Vigilance Task Error
- Reduced Disability
- Reduced Disability Rate
- Reduced Disease Activity
- Reduced Disease Activity Marker Level
- Reduced Disease Progression
- Reduced Disease Symptoms
- Reduced Disease-Related Fatigue
- Reduced Dizziness Handicap Inventory Score
- Reduced Dysphagia
- Reduced Dysphagia Severity
- Reduced Dysphagia Symptom Score
- Reduced EDSS Score
- Reduced Episode Frequency
- Reduced Exacerbation Frequency
- Reduced Exacerbation Rate
- Reduced Exacerbation Risk
- Reduced Exercise-Induced Biochemical Markers
- Reduced Fall Occurrence
- Reduced Fall Rate
- Reduced Fall Risk
- Reduced Fas Ligand Level
- Reduced Fatigue
- Reduced Fatigue Decrement
- Reduced Fatigue During Sprint Repeat Task
- Reduced Fatigue Index
- Reduced Fatigue Levels
- Reduced Fatigue Severity
- Reduced Fatigue-Inertia
- Reduced Free Radical Levels
- Reduced Glial Cell Activation
- Reduced Global Symptoms
- Reduced Glutathione Peroxidase Level
- Reduced Heat Intolerance
- Reduced Heat Stress
- Reduced Histopathological Damage
- Reduced IFN-γ Levels
- Reduced IFN-γ in Serum
- Reduced IL-6 Production
- Reduced Immune Cell Infiltration
- Reduced Immunological Pathway Activity in Antigen Presentation
- Reduced Inflammation Levels
- Reduced Inflammation in Dendritic Cells
- Reduced Inflammatory Biomarker Level
- Reduced Inflammatory Cytokine Secretion from Activated T Cells
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Factor Production
- Reduced Inflammatory Immune Mediators
- Reduced Inflammatory Injury
- Reduced Inflammatory Markers
- Reduced Inflammatory Molecules
- Reduced Inflammatory Pathways
- Reduced Inflammatory Processes
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Stress
- Reduced Intercellular Adhesion Molecule-1
- Reduced Interferon-Gamma Production
- Reduced Interleukin-10 Level
- Reduced Interleukin-10 Levels
- Reduced Interleukin-12 Level
- Reduced Interleukin-2 Level
- Reduced Intracellular Adhesion Molecule-1 Level
- Reduced Lesion Size
- Reduced Leukocyte Trafficking
- Reduced Levels of Anti-Inflammatory Cytokines
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Locomotor Impairment
- Reduced Low-Grade Inflammation
- Reduced Lysophosphatidylethanolamine Level
- Reduced M1 Macrophage Population
- Reduced MCP-3 Level
- Reduced Malonaldehyde Levels
- Reduced Mental Fatigue
- Reduced Monocyte Chemoattractant Protein-1 Level
- Reduced Mononuclear Infiltration in CNS
- Reduced Motor Symptom
- Reduced Multiple Sclerosis Symptom Severity
- Reduced Muscle Degeneration
- Reduced Muscle Symptom
- Reduced Muscular Endurance
- Reduced N-acetylaspartate Level
- Reduced Naïve CD45RA+ Th Cell Count
- Reduced Neurodegenerative Disease-Related Dysfunction
- Reduced Neurogenic Pain
- Reduced Neuroinflammation
- Reduced Neuroinflammatory Markers
- Reduced Neurological Symptoms
- Reduced Neuromuscular Fatigue
- Reduced Neuronal Death
- Reduced Neuropathic Pain
- Reduced Neurotoxicity
- Reduced New Lesion Formation
- Reduced Nuclear Factor Erythroid 2-Related Factor 2 Level
- Reduced Nuclear Factor Kappa-B Level
- Reduced Overall Symptoms
- Reduced Oxidative Damage
- Reduced Oxidative Stress Marker Level
- Reduced Oxidative Stress Markers
- Reduced Oxidative Tissue Injury
- Reduced Oxidized Glutathione Level
- Reduced Paresthesia Symptoms
- Reduced Physical Fatigue
- Reduced Physical Symptoms
- Reduced Plasma IgG Production
- Reduced Post-Void Residual Volume
- Reduced Post-Voiding Residual Volume
- Reduced Pro-Inflammatory Cells
- Reduced Pro-Inflammatory Cytokine Interleukin-15 Levels
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-inflammatory Cytokine Levels
- Reduced Pro-inflammatory Cytokine Production in LPS-stimulated Cells
- Reduced Pro-inflammatory Cytokine Release
- Reduced Pro-inflammatory Effect
- Reduced Proinflammatory Profile
- Reduced Proinflammatory Signaling
- Reduced Proinflammatory/Anti-inflammatory Cytokine Ratios
- Reduced Proliferation of CD4(+) T Cells
- Reduced Psychological Fatigue
- Reduced Rating of Perceived Exertion
- Reduced Reaction Time
- Reduced Regulatory T Cell to Natural Killer Cell Ratio
- Reduced Relapse
- Reduced Relapse Rate
- Reduced Residual Urine Volume
- Reduced Response Time
- Reduced Response Time on Flanker Task
- Reduced Risk of Chronic Inflammatory Diseases
- Reduced Salivary Gamma-Interferon Levels
- Reduced Serious Adverse Events
- Reduced Serum BDNF Levels
- Reduced Serum IL-16 Levels
- Reduced Serum Inflammatory Factors
- Reduced Serum Kynurenine Levels
- Reduced Simple Reaction Time
- Reduced Skin Sensitivity
- Reduced Soiling Rate
- Reduced Soluble CD25 Level
- Reduced Soluble Fas/Fas Ligand Ratio
- Reduced Sprint Time
- Reduced Steroid Load
- Reduced Swimming Time
- Reduced Symptom Frequency
- Reduced T Cell Proliferation
- Reduced T Cell Responsiveness
- Reduced T-Effector Memory Cell Activity
- Reduced TH17 Response
- Reduced TIM-3 Level
- Reduced TNF-α Concentration
- Reduced Th1/Th2 Ratio
- Reduced Th17 Cell Fraction
- Reduced Thermal Pain Sensation
- Reduced Thermal Sensation
- Reduced Thymus and Activation-Regulated Chemokine Level
- Reduced Timed Up and Go Test Time
- Reduced Tiredness
- Reduced Tower of London Test Start Time
- Reduced Transforming Growth Factor-β Level
- Reduced Urinary Urgency
- Reduced Visual Reaction Time
- Reduced Walking Time
- Reduced Weakness
- Reduced White Matter Hyperintensity Severity
- Regulated Blood miRNA Expression
- Regulated Cytokine Levels
- Regulated Immune Response
- Regulated Microglial Activation
- Regulated Oxidative Stress
- Regulated Tryptophan Metabolism
- Reproduced Protective Effect via Extracellular Vesicles
- Restored Regulatory T Cell Population
- Restored T-Cell Population
- Restored Th1/Th2 Cytokine Balance
- Restored Treg Cell Population in MLNs
- Slowed Brain Atrophy Progression
- Slowed Disease Progression
- Slowed Gastric Emptying
- Slowed Neuronal Damage Progression
- Slowed Progression of White Matter Hyperintensities
- Stabilized Cell Membranes
- Stabilized Cytokine Levels
- Stabilized Disease Progression
- Stabilized Natural Killer Cell Activity
- Stabilized Neurofilament Light Chain Level
- Stable Long-Term Function
- Stimulation of Immune Cells
- Th1 Polarized Immune Response Through Activation of moDCs
- Unchanged Heat Shock Protein Levels
- Unchanged IFN-γ Levels
- Worsened Autoimmune Manifestations
- Worsened Cognitive Function
- Worsened Extended Disability Status Score
- Worsened Motor Function
- Worsened Pyramidal Score